{"id":697564,"date":"2024-05-06T18:22:01","date_gmt":"2024-05-06T18:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=697564"},"modified":"2024-05-06T18:22:01","modified_gmt":"2024-05-06T18:22:01","slug":"retinitis-pigmentosa-pipeline-assessment-2024-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-treatment-outlook-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/retinitis-pigmentosa-pipeline-assessment-2024-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-treatment-outlook-companies_697564.html","title":{"rendered":"Retinitis Pigmentosa Pipeline Assessment, 2024 Updates | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest FDA Approvals, Treatment Outlook, Companies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1714995250.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Retinitis Pigmentosa Pipeline Assessment, 2024 Updates | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest FDA Approvals, Treatment Outlook, Companies\" src=\"https:\/\/www.abnewswire.com\/uploads\/1714995250.jpeg\" alt=\"Retinitis Pigmentosa Pipeline Assessment, 2024 Updates | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest FDA Approvals, Treatment Outlook, Companies\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Retinitis Pigmentosa Pipeline Insights<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 45+ key pharma and biotech companies are working on 45+ pipeline drugs in the Retinitis Pigmentosa therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\">&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Retinitis Pigmentosa Pipeline Insight, 2024<\/strong><\/a>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Retinitis Pigmentosa Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Retinitis Pigmentosa Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\"  target=\"_blank\"><strong>Retinitis Pigmentosa Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The report provides detailed insights into the emerging therapies for the&nbsp;<strong>treatment of Retinitis Pigmentosa<\/strong>&nbsp;and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li>\n<p>It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li>\n<p>It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li>\n<p>It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the&nbsp;<strong>Retinitis Pigmentosa market<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><em>The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Retinitis Pigmentosa &ndash; Emerging Therapies Mechanism of Action (MOA)<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Gene transference<\/p>\n<\/li>\n<li>\n<p>Cell replacements<\/p>\n<\/li>\n<li>\n<p>Integrin inhibitors<\/p>\n<\/li>\n<li>\n<p>Cell replacements; Nerve growth factor modulators<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Retinitis Pigmentosa &ndash; Route of Administration&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">Retinitis Pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as &ndash;<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Oral<\/p>\n<\/li>\n<li>\n<p>Parenteral<\/p>\n<\/li>\n<li>\n<p>Intravitreal<\/p>\n<\/li>\n<li>\n<p>Subretinal<\/p>\n<\/li>\n<li>\n<p>Topical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Products have been categorized under various Molecule types, such as &ndash;&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Monoclonal Antibody<\/p>\n<\/li>\n<li>\n<p>Peptides<\/p>\n<\/li>\n<li>\n<p>Polymer<\/p>\n<\/li>\n<li>\n<p>Small molecule<\/p>\n<\/li>\n<li>\n<p>Gene therapy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Analysis of Emerging Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The report covers the emerging products under different phases of clinical development like &ndash;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Late-stage products (Phase III)<\/p>\n<\/li>\n<li>\n<p>Mid-stage products (Phase II)<\/p>\n<\/li>\n<li>\n<p>Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li>\n<p>Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li>\n<p>Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Learn How the Ongoing Clinical &amp; Commercial Activities will Affect the Retinitis Pigmentosa Therapeutic Segment @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\"  target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/retinitis-pigmentosa-retinitis-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Retinitis Pigmentosa Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\"><em>Currently, there is no therapy that can stop the evolution of pigmentary retinopathies or restore vision. Management of retinitis pigmentosa includes dietary supplements, ozone therapy, surgery, etc. Gene therapy-based treatments are under research focus for the treatment of Retinitis pigmentosa.<\/em><\/p>\n<p style=\"text-align: justify;\">There are approx.<strong>&nbsp;45+ key companies<\/strong>&nbsp;developing therapies for Retinitis Pigmentosa. Currently,&nbsp;<strong>Biogen<\/strong>&nbsp;is leading the therapeutics domain with its Retinitis Pigmentosa drug candidates in the most advanced stage of clinical development.<\/p>\n<p style=\"text-align: justify;\"><strong>The Leading Companies in the Retinitis Pigmentosa Therapeutics Market Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Allegro Ophthalmics<\/p>\n<\/li>\n<li>\n<p>Allergan<\/p>\n<\/li>\n<li>\n<p>Biogen<\/p>\n<\/li>\n<li>\n<p>Domp&eacute; Farmaceutici<\/p>\n<\/li>\n<li>\n<p>Editas Medicine<\/p>\n<\/li>\n<li>\n<p>Horama<\/p>\n<\/li>\n<li>\n<p>ID Pharma<\/p>\n<\/li>\n<li>\n<p>Ionis Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>jCyte<\/p>\n<\/li>\n<li>\n<p>MeiraGTx<\/p>\n<\/li>\n<li>\n<p>Nacuity Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>Neurotech<\/p>\n<\/li>\n<li>\n<p>Nightstar Therapeutics\/Biogen<\/p>\n<\/li>\n<li>\n<p>Novartis Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>OiDE OptoEye<\/p>\n<\/li>\n<li>\n<p>ReNeuron<\/p>\n<\/li>\n<li>\n<p>ReNeuron<\/p>\n<\/li>\n<li>\n<p>Sanofi (Terminated)<\/p>\n<\/li>\n<li>\n<p>SparingVision<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;And Many Others<\/p>\n<p style=\"text-align: justify;\"><strong>Retinitis Pigmentosa Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>BIIB-112: Biogen<\/p>\n<\/li>\n<li>\n<p>QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>ALG-1001: Allegro Ophthalmics\/Hanmi Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>NPI 001: Nacuity Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>AAV8- RPGR\/BIIB1121: Nightstar Therapeutics\/Biogen<\/p>\n<\/li>\n<li>\n<p>ReN 003: ReNeuron<\/p>\n<\/li>\n<li>\n<p>jCell: jCyte<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And Many More<\/p>\n<p style=\"text-align: justify;\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\"  target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/retinitis-pigmentosa-retinitis-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Retinitis Pigmentosa Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Retinitis Pigmentosa &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Retinitis Pigmentosa Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Retinitis Pigmentosa Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Retinitis Pigmentosa Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Retinitis Pigmentosa Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Retinitis Pigmentosa Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Key Companies in the Retinitis Pigmentosa Market<\/p>\n<p style=\"text-align: justify;\">15. Key Products in the Retinitis Pigmentosa Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Retinitis Pigmentosa Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Retinitis Pigmentosa Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Retinitis Pigmentosa Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF to Explore the Key Offerings of the Report:&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/retinitis-pigmentosa-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\"  target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/retinitis-pigmentosa-retinitis-pipeline-insight<\/strong><\/a><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=retinitis-pigmentosa-pipeline-assessment-2024-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-treatment-outlook-companies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=retinitis-pigmentosa-pipeline-assessment-2024-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-treatment-outlook-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Retinitis Pigmentosa Pipeline Insights As per DelveInsight\u2019s assessment, globally, about 45+ key pharma and biotech companies are working on 45+ pipeline drugs in the Retinitis Pigmentosa therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA) and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/retinitis-pigmentosa-pipeline-assessment-2024-updates-indepth-insights-into-the-clinical-trials-emerging-drugs-latest-fda-approvals-treatment-outlook-companies_697564.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-697564","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/697564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=697564"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/697564\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=697564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=697564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=697564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}